Bluebird shares at six-year low following hematologic malignancies in sickle cell trial

Gene therapy company bluebird is temporarily suspending two clinical trials of its sickle cell candidate while it sorts out the causes of two new hematologic malignancies, and has paused marketing of its approved therapy as a matter of caution.

The disclosures sent shares of bluebird bio Inc. (NASDAQ:BLUE) to a six-year low, shaving more than $1 billion from its market cap as the stock sank $17.32 (38%) to $28.44 Tuesday...